沙利度胺联合FOLFIRI方案治疗晚期结肠直肠癌的临床观察  

Clinical observation in thalidomide combined with FOLFIRI in treatment of advanced colorectal cancer

作　　者：王琼[1] 许晨[1] 王南瑶[1] 盛华明[1] 费燕华[1] 吴丹[1] 

机构地区：[1]东南大学医学院附属江阴人民医院肿瘤科,江阴214400

出　　处：《癌症进展》2009年第4期460-461,471,共3页Oncology Progress

摘　　要：目的观察沙利度胺联合FOLFIRI方案治疗晚期结直肠癌的疗效及安全性。方法26例符合入组条件的晚期结肠直肠癌患者采用伊立替康(CPT-11)+5-氟尿嘧啶(5-Fu)+亚叶酸钙(LV)方案(即FOLFIRI方案)联合沙利度胺化疗。结果本组CR3例,PR9例,NC8例,有效率(CR+PR)为46.15%(12/26),临床获益率为76.92%;中位疾病进展时间(TTP)为4.5个月;主要毒副作用为恶心呕吐、粘膜炎、腹痛、腹泻、血液学毒性。结论沙利度胺联合FOLFIRI方案治疗晚期结肠直肠癌疗效确切,患者耐受性好。Objective To compare the efficiency and safety of FOLFIRI combined with thalidomide in treating advanced colorectal cancer.Methods Totally 26 patients with advanced colorectal cancer were treated by 5-fluorouracil,leucovorin,and irinotecan combined with thalidomide.Results The overall response rates（CR＋PR） were 46.15%,and the median TTP was 4.5 months.The major toxicities were nausea,vomiting,delayed diarrhea,abdominal pain,and bone marrow depression.Conclusion FOLFIRI combined with thalidomide is an effective and tolerable therapy for advanced colorectal cancer.

关 键 词：晚期结肠直肠癌 联合治疗 沙利度胺 

分 类 号：R735.3[医药卫生—肿瘤]